baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Provectus Biopharmaceuticals, Inc.../ US74373P1084 /

5/17/2024 9:54:20 PM	Chg. -0.0013	Volume	Bid-	Ask-	High	Low
0.1929USD	-0.67%	351,993 Turnover: 63,917.8310	-Bid Size: -	-Ask Size: -	0.1929	0.1610

GlobeNewswire 5/14 Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial...

GlobeNewswire 5/2 Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of...

GlobeNewswire 4/18 Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Pro...

GlobeNewswire 4/16 Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder...

GlobeNewswire 4/11 Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC a...

GlobeNewswire 3/27 Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miam...

GlobeNewswire 3/12 Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Benga...

GlobeNewswire 3/7 Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC a...

GlobeNewswire 2/29 Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstrac...

GlobeNewswire 2/15 Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call

GlobeNewswire 2/14 Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services

GlobeNewswire 12/18/2023 Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodiu...

GlobeNewswire 11/15/2023 Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutane...

GlobeNewswire 11/13/2023 Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uvea...

GlobeNewswire 11/6/2023 Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at So...

GlobeNewswire 3/24/2022 Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule

GlobeNewswire 2/16/2022 Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for O...

GlobeNewswire 2/8/2022 Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at Amer...

GlobeNewswire 1/27/2022 Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adju...

GlobeNewswire 1/10/2022 Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal’s Activity Ag...

GlobeNewswire 11/1/2021 Provectus Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Single-Agent PV-10® ...

GlobeNewswire 10/28/2021 Provectus Biopharmaceuticals Announces Presentation of Updated Data from Combination Therapy Trial o...

GlobeNewswire 10/4/2021 Provectus Biopharmaceuticals Provides Update on Research into Oral Administration of PV-10® Immunoth...

GlobeNewswire 9/27/2021 Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melan...

GlobeNewswire 9/21/2021 Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrin...

Provectus Biopharmaceuticals, Inc.../ US74373P1084 /

If you wish to receive reply to your feedback, please provide your email address.